AKT1 and ovarian carcinoma: Collectively, results of the present study demonstrated that baicalein improves the sensitivity of ovarian cancer cells to cisplatin via inhibiting CirSLC7A6/miR-2682-5p/SLC7A6, and further inactivating PI3K/Akt/mTOR and Erk/p38 MAPK pathways.